Maxigen Biotech Inc.
Maxigen Biotech Inc., a leading player in the biotechnology sector, is headquartered in Taiwan (TW) and operates extensively across Asia and beyond. Founded in 2000, the company has established itself as a pioneer in the development of innovative biopharmaceuticals and advanced diagnostic solutions. Specialising in the production of recombinant proteins, monoclonal antibodies, and cell culture products, Maxigen Biotech stands out for its commitment to quality and cutting-edge technology. The company’s unique offerings cater to various industries, including pharmaceuticals, diagnostics, and research. With a strong market position, Maxigen Biotech has achieved significant milestones, including collaborations with major research institutions and a robust portfolio of patented technologies. This dedication to innovation and excellence has solidified its reputation as a trusted partner in the global biotech landscape.
DitchCarbon Score
How does Maxigen Biotech Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Maxigen Biotech Inc.'s score of 19 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Maxigen Biotech Inc.'s reported carbon emissions
In 2022, Maxigen Biotech Inc. reported total carbon emissions of approximately 1,566,000 kg CO2e, comprising 1,566,000 kg CO2e from Scope 1, 3,000 kg CO2e from Scope 2, and 1,563,000 kg CO2e from Scope 3 emissions. This marked a reduction from 2021, where total emissions were about 1,712,700 kg CO2e, with 1,712,700 kg CO2e from Scope 1, 3,700 kg CO2e from Scope 2, and 1,709,000 kg CO2e from Scope 3. Despite these reductions, Maxigen Biotech Inc. has not publicly disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The company continues to monitor its emissions across all scopes, focusing on improving its carbon footprint in alignment with industry standards.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Get Started| 2021 | 2022 | |
|---|---|---|
| Scope 1 | 1,712,700 | 0,000,000 |
| Scope 2 | 3,700 | 0,000 |
| Scope 3 | 1,709,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Maxigen Biotech Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
